Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06372457 · ClinicalTrials.gov registry record
COLLIGO-HCM: A Multinational Observational Study of the Real-World Effectiveness of Mavacamten Among Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM)
A clinical trial of Hypertrophic Cardiomyopathy (HCM), sponsored by Bristol-Myers Squibb.
- Active
- Registry status
- 500
- Enrollment target
- 1
- Study location
NCT06372457: Active study of Hypertrophic Cardiomyopathy (HCM), sponsored by Bristol-Myers Squibb.
NCT06372457 is a study of Hypertrophic Cardiomyopathy (HCM) that is active but no longer recruiting, run by Bristol-Myers Squibb. The registered enrollment target is 500 participants. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06372457, a study of Hypertrophic Cardiomyopathy (HCM), is active but no longer recruiting, sponsored by Bristol-Myers Squibb.
- ACTIVE NOT RECRUITING
- Registry status
- 500 participants
- Enrollment target
- 1
- Study location
Study Summary
COLLIGO-HCM is a global observational study that will conduct observational research of hypertrophic cardiomyopathy (HCM) treatment in real-world clinical practice.
Conditions Studied
Interventions
- DRUG Mavacamten
- DRUG Approved Hypertrophic Cardiomyopathy drug treatments
Study Locations (1)
North Carolina
- IQVIA - Durham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 500 participants |
| Start Date | 2023-12-01 |
| Est. Completion | 2025-06-15 |
What the registry record for NCT06372457 still lists
NCT06372457 is an observational study that tracks outcomes without assigning an intervention. The registered 500 participants enrollment target is mid-sized for trials with a published cap.
The record links to 1 condition, with Hypertrophic Cardiomyopathy (HCM) appearing as the primary indexed condition, and to 2 interventions - of which Mavacamten is the first listed.
NCT06372457 reports a single indexed study location in North Carolina.
Frequently Asked Questions
What is clinical trial NCT06372457 about?
NCT06372457 is a clinical study titled "COLLIGO-HCM: A Multinational Observational Study of the Real-World Effectiveness of Mavacamten Among Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM)". COLLIGO-HCM is a global observational study that will conduct observational research of hypertrophic cardiomyopathy (HCM) treatment in real-world clinical practice.
What is the current status of trial NCT06372457?
This trial is currently active not recruiting. The enrollment target is 500 participants. The study started on 2023-12-01. Estimated completion is 2025-06-15.
What conditions does trial NCT06372457 study?
This clinical trial studies the following conditions: Hypertrophic Cardiomyopathy (HCM).
What interventions are being tested in trial NCT06372457?
The interventions under investigation include: Mavacamten (DRUG), Approved Hypertrophic Cardiomyopathy drug treatments (DRUG).
Who is sponsoring clinical trial NCT06372457?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06372457 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hypertrophic Cardiomyopathy (HCM)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00001230 · 500 participants
Host Response to Infection and Treatment in Filarial Diseases
- NCT00001529 · 500 participants
Improved Methods of Cell Selection for Bone Marrow Transplant Alternatives
- NCT00697411 · 500 participants
Study of Selected X-Linked Disorders: Aicardi Syndrome
- NCT00903110 · 500 participants
Global Patient Registry to Monitor Long-term Safety and Effectiveness of Increlex® in Children and Adolescents With Severe Primary Insulin-like Growth Factor-1 Deficiency (SPIGFD).
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI